Journals / Archives of Rheumatology / 2021 / Cilt: 36 - Sayı: 3

Predictive factors of mortality in granulomatosis with polyangiitis:A single-center study

Pages
435–444
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These patients shouldbe followed more closely and carefully to improve survival.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: The aim of this study was to identify predictors of mortality in granulomatosis with polyangiitis (GPA) patients and to seek the ways ofimproving survival in GPA patients.
📊
Key Findings & Data:Patients and methods: Between January 2005 and June 2020, a total of 60 patients (26 males, 34 females; median age: 49 years; range, 19 to 75years) who were diagnosed with GPA were retrospectively analyzed.
💡
Conclusion & Impact:These patients shouldbe followed more closely and carefully to improve survival.
🔬Design:Research Article
📍Scope:2005 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: The aim of this study was to identify predictors of mortality in granulomatosis with polyangiitis (GPA) patients and to seek the ways ofimproving survival in GPA patients. Patients and methods: Between January 2005 and June 2020, a total of 60 patients (26 males, 34 females; median age: 49 years; range, 19 to 75years) who were diagnosed with GPA were retrospectively analyzed. Demographic, clinical, laboratory, and radiological findings of all patients wererecorded. Survival rates were analyzed using the Kaplan-Meier plot. Results: The median follow-up was 36 months, and 10 (16.7%) patients died during the study period. Univariate analysis showed that theprognostic values were attributed to high serum creatinine levels (>2.1 mg/dL; p=0.01), proteinuria (p=0.01), dialysis-requiring renal damage atthe time of diagnosis (p=0.01) or at any time during follow-up (p=0.01), low lymphocyte levels (p=0.01), hypoalbuminemia (p=0.04), absence ofupper respiratory tract involvement (p=0.01), presence of lung involvement with cavitary lesions (p=0.01), high Birmingham Vascular Activity Score(p=0.02), and history of serious infection (p=0.01). In the multivariate analysis, the presence of renal damage requiring dialysis at any time duringfollow-up (relative risk [95% confidence interval]: 21 [4.1-18.3]; p=0.01) was found to be an independent predictor of mortality. Immunosuppressivedrugs exerted no effect on mortality, and the most common causes of death were infections (50%). Conclusion: The presence of dialysis-requiring renal damage is the most important risk factor for mortality in GPA patients. These patients shouldbe followed more closely and carefully to improve survival.

🔖

Cite This Article

TEKKARIŞMAZ, N., TUFAN, M. A. (2022). Predictive factors of mortality in granulomatosis with polyangiitis:A single-center study. Archives of Rheumatology, Cilt: 36 - Sayı: 3, 435–444. https://ajindex.com/articles/448020

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Greco A, Marinelli C, Fusconi M, Macri GF, Gallo A, De Virgilio A, et al. Clinic manifestations in granulomatosis with polyangiitis. Int J Immunopathol Pharmacol 2016;29:151-9
  2. Bligny D, Mahr A, Toumelin PL, Mouthon L, Guillevin L. Predicting mortality in systemic Wegener's granulomatosis: a survival analysis based on 93 patients. Arthritis Rheum 2004;51:83-91
  3. King C, Harper L, Little M. The complications of vasculitis and its treatment. Best Pract Res Clin Rheumatol 2018;32:125-36
  4. Emejuaiwe N. Treatment strategies in ANCA-associated vasculitis. Curr Rheumatol Rep 2019;21:33
  5. Little MA, Nightingale P, Verburgh CA, Hauser T, De Groot K, Savage C, et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2010;69:1036-43
  6. Titeca-Beauport D, Francois A, Lobbedez T, Guerrot D, Launay D, Vrigneaud L, et al. Early predictors of one-year mortality in patients over 65 presenting with ANCA-associated renal vasculitis: a retrospective, multicentre study. BMC Nephrol 2018;19:317
  7. Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 1990;33:1101-7
  8. Ahn SS, Jung SM, Song JJ, Park YB, Lee SW. Controlling nutritional status score is associated with all-cause mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Yonsei Med J 2019;60:1164-73
  9. Mukhtyar C, Luqmani R. Disease-specific quality indicators, guidelines, and outcome measures in vasculitis. Clin Exp Rheumatol 2007;25(6 Suppl 47):120-9
  10. Biedroń G, Włudarczyk A, Wawrzycka-Adamczyk K, Wójcik K, Sznajd J, Zdrojewski Z, et al. Treatment and its side effects in ANCA-associated vasculitides - Study based on POLVAS registry data. Adv Med Sci 2020;65:156-62
  11. Solans-Laqué R, Fraile G, Rodriguez-Carballeira M, Caminal L, Castillo MJ, Martínez-Valle F, et al. Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides: Impact of the vasculitis type, ANCA specificity, and treatment on mortality and morbidity. Medicine (Baltimore) 2017;96:e6083
  12. Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011;70:488-94. 13. de Joode AAE, Sanders JSF, Puéchal X, Guillevin LP, Hiemstra TF, Flossmann O, et al. Long term azathioprine maintenance therap